NCT03041987Active, not recruiting
Chinese Cohort Study of Chronic Kidney Disease
Source: ClinicalTrials.gov · Last updated 18 Nov 2023
Brief summary (registry, in English)
This study aimed to explore underlying mechanisms of chronic kidney disease progression and its association with adverse consequences. It will enroll approximately 5000 pre-dialysis chronic kidney disease patients aged between 18 and 74 years in mainland China and follow-up for at least 5 years. Questionnaires, anthropometric measures, laboratory tests, and biomaterials will be collected at baseline and annually. The principal clinical outcomes of the study consist of renal disease events, cardiovascular events, and death.
- Status (registry)
- Active, not recruiting
- Study type
- Observational
- Enrollment
- 5000 (estimated)
- First submitted
- 2 Feb 2017
- Start date
- 1 Jan 2012
- Primary completion date
- 31 Dec 2026
- Lead sponsor
- Peking University First Hospital
- Diseases
- Chronic kidney disease
- NCT number
- NCT03041987
What you commit to
- Study type: Observational
- Planned participants: 5000
- From 1 Jan 2012 to the primary completion date, 31 Dec 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Treated with immunosuppressive agents in the preceding 6 months to treat renal or immune disease.
- Malignancy treated with chemotherapy within last 2 years.
- Renal or other transplantation.
Other illness
- NYHA Class III or IV heart failure.
- Chronic kidney disease caused by systemic inflammatory illness or autoimmune disease, such as lupus erythematosus.
- Self-reported or known diagnosis of HIV infection and/or AIDS.
- Hereditary kidney disease.
Other
- Participants meeting even one of the listed items should be excluded.
- Isolated hematuria.
- Self-reported or known diagnosis of cirrhosis.
- Pregnant or breast-feeding women.
- Participation in interventional clinical trial.
Who the study is looking for
- Participants should meet the following criteria of enrollment according to their etiology of nephrology.
- For glomerular nephrology patients, the estimated glomerular filtration rate (eGFR) should be ≥15 ml/minute per 1.73m(2).
- For diabetic nephrology patients, the defining eligibility was 15 ml/minute per 1.73m(2) ≤eGFR\<60 ml/minute per 1.73m(2) or eGFR≥ 60 ml/minute per 1.73m(2) with "nephrotic range" proteinuria, which is defined as 24-hour urinary protein ≥3.5 g or urinary albumin creatinine ratio (ACR) ≥2 000 mg/g or corresponding values of urine dipstick test or urinary protein creatinine ratio (PCR).
- For non-glomerular nephrology and non-diabetic nephrology patients, 15 ml/minute per 1.73m(2)≤eGFR\<60 ml/minute per 1.73m(2) is set for enrollment.
Age in the registry: 18 years to 74 years · Sex: All
Sites (1)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Peking University First Hospital Coordinator of this site? Confirm its status | Beijing | China | Unknown status |
Related publications
- Urinary magnesium predicts risk of cardiovascular disease in Chronic Kidney Disease stage 1-4 patients.Clin Nutr · 2021 · PMID 33160701
This page is information, not medical advice. Discuss any trial with your doctor.